Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Cost‐effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma
Pandya, Chintan , Hashmi, Shahrukh K. , Khera, Nandita , Dispenzieri, Angela , Siddiqui, Mustaqeem , Noyes, Katia , Kumar, Shaji , Gertz, Morie A. , Hogan, William J. , Dispenzieri, Angela , Siddiqui, Mustaqeem A

Clinical Transplantation | July 17, 2014 | Volume: 28 | Issue: 10 | Pages: 1084-1091

10.1111/ctr.12421 | PMID 25040732 Get It

AbstractBackgroundAutologous stem cell transplant (ASCT) is the current standard of care for most patients with multiple myeloma (MM) who are transplant eligible, yet the timing ofASCTis disputed due to a similar overall (OS) and progression‐free survival with an earlyASCT(eASCT) or a delayedASCT(dASCT) approach.ObjectiveWe developed a decision analytic model to perform cost‐effectiveness analysis of the two commonly used treatment strategies forMM.MethodsData on disease progression and treatment effectiveness came from 2001 to 2008 cohort treated at the Mayo Clinic and from published studies. Cost analysis was performed from a third‐party payer perspective.ResultsThe Consumer Price Index adjusted 2012 costs ofeASCTanddASCTwere $249 236 and $262 610, respectively.eASCTcohort had a benefit of 1.96 quality‐adjusted life years (QALYs), 0.23 QALYs more thandASCT, implying thateASCTis preferred (dominant) overdASCT. The most critical variables in one‐way sensitivity analysis were treatment‐related mortality and OS associated witheASCTstrategy.ConclusionsWe conclude thateASCTcould potentially be a relatively cost‐effective treatment option for appropriate patients with MM, and these results would help patients, providers, and payers in decision making for timing of ASCT.
Outcome and Management of Pacemaker‐Induced Superior Vena Cava Syndrome
Fu, Hai‐Xia , Huang, Xinmiao , Zhong, Li , Osborn, Michael J., Bjarnason, Haraldur , Mulpuru, Siva K. , Zhao, Xianxian , Friedman, Paul A. , Cha, Yong‐Mei , Bjarnason, Haraldur

Pacing and Clinical Electrophysiology | July 17, 2014 | Volume: 37 | Issue: 11 | Pages: 1470-1476

10.1111/pace.12455 | PMID 25040311 Get It

BackgroundWe aimed to determine the long‐term outcomes of percutaneous lead extraction and stent placement in patients with pacemaker‐induced superior vena cava (SVC) syndrome.MethodsThe study retrospectively screened patients who underwent lead extraction followed by central vein stent implantation at Mayo Clinic (Rochester, MN, USA), from January 2005 to December 2012, to identify the patients with pacemaker‐induced SVC syndrome. Demographic, clinical, and follow‐up characteristics of those patients were collected from electronic medical records.ResultsSix cases were identified. The mean (standard deviation) age was 56 (15) years (male, 67%). All patients had permanent dual‐chamber pacemakers, with a mean 11‐year history of pacemaker placement. The entire device system was explanted in five patients; one patient had a 21‐year‐old pacemaker lead that could not be removed. Eight stents were implanted in six patients: five patients had one stent, one patient had three. A new pacemaker system was reimplanted through the stented vein in five patients. Technical success was achieved in all patients, without any complication. Symptoms rapidly resolved in all patients after stent deployment. The mean follow‐up duration was 48 months (range, 10–100 months). Three patients remained symptom free. Reintervention with percutaneous balloon venoplasty was successful in three patients with symptom recurrence.ConclusionPercutaneous stent implantation after lead removal followed by reimplantation of leads is a feasible alternative therapy for pacemaker‐induced SVC syndrome, although some cases may require repeat intervention.
Clinical Significance of Low-Positive Histoplasma Urine Antigen Results
Theel, Elitza S. , Ramanan, Poornima

Journal of Clinical Microbiology | July 17, 2014 | Volume: 52 | Issue: 9 | Pages: 3444-3446

10.1128/jcm.01598-14 | PMID 25031433 Get It

ABSTRACT Histoplasma urine antigen (UAg) detection is an important biomarker for histoplasmosis. The clinical significance of low-positive (<0.6 ng/ml) UAg results was evaluated in 25 patients without evidence of prior Histoplasma infection. UAg results from 12/25 (48%) patients were considered falsely positive, suggesting that low-positive UAg values should be interpreted cautiously.
De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study
Hasserjian, Robert P. , Campigotto, Federico, Klepeis, Veronica, Fu, Bin , Wang, Sa A. , Bueso‐Ramos, Carlos E. , Cascio, Michael J. , Soderquist, Craig , Bagg, Adam , Yan, Jiong , Ochs, Rachel, Orazi, Attilio , Moore, Frank, Mahmoud, Amer, George, Tracy I. , Foucar, Kathryn , Odem, Jamie L., Booth, Cassie, Morice, William G. , Stone, Richard M. , Rogers, Heesun J. , Hsi, Eric D. , Morice, William George , DeAngelo, Daniel J. , Steensma, David P. , Neuberg, Donna , Arber, Daniel A. , Cascio, M J , George, Tracy I , Orazi, Attilio

American Journal of Hematology | July 17, 2014 | Volume: 89 | Issue: 11 | Pages: No page available

10.1002/ajh.23808 | PMID 25042343 Get It

It is controversial whether acute myeloid leukemia (AML) patients with 20–29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10–19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4‐year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P < 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P < 0.0001), and stem cell transplant (P < 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML. Am. J. Hematol. 89:E193–E199, 2014. © 2014 Wiley Periodicals, Inc.
SCAI/ACC/AHA Expert Consensus Document
Dehmer, Gregory , Blankenship, James C. , Dwyer, James G., Feldman, Dmitriy N. , Gardner, Timothy J., Singh, Mandeep, Çilingiroğlu, Mehmet , Grines, Cindy L.

Catheterization and Cardiovascular Interventions | July 16, 2014 | Volume: 84 | Issue: 2 | Pages: 169-187

10.1002/ccd.25371 | PMID 25045090 Get It

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Dimopoulos, Meletios Α. , Kastritis, Efstathios , Owen, Roger G., Kyle, Robert A. , Morra, Enrica, Leleu, Xavier , García‐Sánz, Ramón , Munshi, Nikhil C. , Terpos, Evangelos , Ghobrial, Irene M. , Morel, Pierre , Maloney, David G. , Rummel, Mathias , Leblond, Véronique , Advani, Ranjana H. , Kyriakou, Charalampia , Barlogie, Bart , Gregory, Stephanie A., Kimby, Eva , Merlini, Giampaolo , Landgren, Ola , Anderson, Kenneth C. , Gertz, Morie A. , Thomas, Sheeba K. , Treon, Steven P. , Merlini, Giampaolo , Dimopoulos, Meletios A , Terpos, Evangelos , Advani, Ranjana H , Kastritis, Efstathios , Garcia-Sanz, Ramon , Ghobrial, Irene M

Blood | July 16, 2014 | Volume: 124 | Issue: 9 | Pages: 1404-1411

10.1182/blood-2014-03-565135 | PMID 25027391 Get It

Abstract Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)
Gritz, Ellen R., Arnold, Kathryn B. , Moinpour, Carol M. , Burton‐Chase, Allison M. , Probstfield, Jeffrey F., See, William A., Lieber, Michael M., Caggiano, Vincent , Moody‐Thomas, Sarah, Szczepanek, Connie M. , Ryan, Anne, Carlin, Susie M., Hill, Shannon , Goodman, Phyllis J. , Padberg, Rose Mary, Minasian, Lori M. , Meyskens, Frank L. , Thompson, Ian M. , Tangen, Catherine M. , Thompson, Ian M

Cancer Epidemiology, Biomarkers & Prevention | July 16, 2014 | Volume: 23 | Issue: 8 | Pages: 1638-1648

10.1158/1055-9965.epi-14-0202 | PMID 25028457 Get It

Abstract Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebo-controlled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6, 13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P &lt; 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P &lt; 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials. Cancer Epidemiol Biomarkers Prev; 23(8); 1638–48. ©2014 AACR.
Message in a bottle: decoding medication injury patterns in the gastrointestinal tract
Voltaggio, Lysandra , Lam‐Himlin, Dora , Limketkai, Berkeley N. , Arnold, Christina A. , Singhi, Aatur Dilip

Journal of Clinical Pathology | July 16, 2014 | Volume: 67 | Issue: 10 | Pages: 903-912

10.1136/jclinpath-2014-202511 | PMID 25028528 Get It

Medication injury in the gastrointestinal tract (GIT) is a rapidly evolving topic. Increasing endoscopy together with an ageing population, polypharmacy, and a burgeoning drug industry offer heightened opportunities to observe the unintended side effects of therapeutic ingestants. In this review, we emphasise the most commonly encountered medication injuries involving the GIT, as well as emerging agents and mimics. While topics are organised by organ system, the reader should keep in mind that injury patterns are generally not site-specific. As such, awareness of these major morphologic patterns can be translated to multiple tissue sites to more broadly facilitate the diagnostic process.
MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease
Ferman, Tanis J. , Smith, Glenn E. , Maroney‐Smith, Mandie, Spychalla, Anthony J., Jack, Clifford R. , Petersen, Ronald C. , Kantarci, Kejal , Maroney-Smith, Mandie, Zhang, Bing , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R , Kantarci, Kejal , Ferman, Tanis J

Journal of Neuroimaging | July 16, 2014 | Volume: 25 | Issue: 2 | Pages: 269-274

10.1111/jon.12138 | PMID 25039916 Get It

ABSTRACTBACKGROUND AND PURPOSEMild cognitive impairment (MCI) precedes both Alzheimer's disease (AD) dementia and with Lewy bodies (DLB). We investigated proton magnetic resonance spectroscopy (MRS) characteristics of MCI patients who progressed to DLB compared to those who progressed to AD dementia or remained stable.METHODSConsecutive MCI patients who underwent single voxel MRS at baseline and progressed to DLB (n = 10) were identified during a median follow‐up period of 18 months. From the same cohort, we identified age‐ and sex‐matched MCI patients who progressed to AD dementia (n = 27) or remained stable (n = 20) during a similar follow‐up period. This study was approved by the Institutional Review Board and informed consent was from every subject.RESULTSMCI patients who progressed to AD dementia were characterized by lower N‐acetylaspartate (NAA)/Cr ratio in the posterior cingulate voxel compared to those who progressed to DLB (P = .001). Decreased NAA/Cr in the posterior cingulate voxel differentiated MCI patients who progressed to DLB from those who progressed to AD with an area under the receiver operating characteristic curve of .85 (P < .001) on logistic regression analysis.CONCLUSIONSMRS may be useful in differentiating MCI patients with prodromal AD dementia from those with prodromal DLB for early disease‐specific interventions.
Initial External Validation of REGRESS in Public Health Graduate Students
Kidwell, Kelley M. , Enders, Felicity B., Enders, Felicity B.

Clinical and Translational Science | July 16, 2014 | Volume: 7 | Issue: 6 | Pages: 447-455

10.1111/cts.12190 | PMID 25041650 Get It

AbstractLinear regression is typically taught as a second and potentially last required (bio)statistics course for Public Health and Clinical and Translational Science students. There has been much research on the attitudes of students toward basic biostatistics, but there has not been much assessing students’ understanding of critical regression topics. The REGRESS (REsearch on Global Regression Expectations in StatisticS) quiz developed at Mayo Clinic utilizes 27 questions to assess understanding for simple and multiple linear regression. We performed an initial external validation of this tool with 117 University of Michigan public health students. We compare the results of pre‐ and postcourse quiz scores from the Michigan cohort to scores of Mayo medical students and professional statisticians. University of Michigan students performed higher than Mayo students on the precourse quiz due to previous related coursework, but did not perform as high postcourse indicating the need for course modification. In the Michigan cohort, REGRESS scores improved by a mean (standard deviation) of 4.6 (3.4), p < 0.0001. Our results support the use of the REGRESS quiz as a learning tool for students and an evaluation tool to identify topics for curricular improvement for teachers, while we highlight future directions of research.